News
Dr Daniel Ubelhart, world renowned expert in the field of osteoarthritis, reviewed the latest clinical evidences of the efficacy of chondroitin sulfate in the treatment of osteoarthritis.Proven efficacy and high security profile, major conclusions of his paper
Beneath the skinConference on psoriatic osteoarthritis and other chronic inflammatory diseases
This rheumatic disease affects 24% of Spaniards aged 45 and olderIt is estimated that by 2020 osteoarthritis will become the fourth most common cause of disability because of the population longer life expectancy and progressive ageing.Apart from ageing, the other factors leading to the development of osteoarthritis are obesity, genetic predisposition and joint overuse.The role of family physi
Elite competition, injuries and joint overuse, among the major risk factors that may end up causing osteoarthritis.Dr. Villalón, head of the Club Atlético de Madrid medical department, points out that the chances of a sportsperson of developing osteoarthritis increase after suffering a knee trauma.
MOVES is a new multicenter clinical essay involving 560 patients from Spain, Germany, France and Poland.The aim of the MOVES project (Multicenter Osteoarthritis InterVEntion trial with Sysadoas) is to contribute further evidence of the efficacy and security of the combination of chondroitin sulfate and glucosamine in the treatment of knee osteoarthritis patients with moderate to severe pain.